• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Health professionals are encouraged to take the Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …

Background: In patients with type 2 diabetes mellitus, sodium-glucose cotransporter 2
inhibitors reduce the risk of hospitalization for heart failure (HHF). We assessed the effect of …

Type 2 diabetes mellitus is a risk factor for incident heart failure and increases the risk of
morbidity and mortality in patients with established disease. Secular trends in the …

The coexistence of type 2 diabetes mellitus (T2DM) and heart failure (HF), either with
reduced (HFrEF) or preserved ejection fraction (HFpEF), is frequent (30–40% of patients) …

An increasing amount of evidence reveals that the gut microbiota is involved in the
pathogenesis and progression of various cardiovascular diseases. In patients with heart …

Aims To examine the manifestation of cardiovascular or renal disease (CVRD) in patients
with type 2 diabetes (T2D) initially free from CVRD as well as the mortality risks associated …

Heart failure (HF) is common and associated with a poor prognosis, despite advances in
treatment. Over the last decade cardiovascular outcome trials with sodium–glucose co …

Type 2 diabetes mellitus (T2DM) is common in patients with heart failure (HF) and
associated with considerable morbidity and mortality. Significant advances have recently …

Type 2 diabetes mellitus (T2DM) is a worldwide major health burden and heart failure (HF)
is the most common cardiovascular (CV) complication in affected patients. Therefore …